Endocervical Adenocarcinoma Characterization and Diagnostic Techniques

Endocervical adenocarcinoma constitutes a growing proportion of cervical malignancies and is broadly classified into human papillomavirus-associated and human papillomavirus-independent subtypes. Tumour characterisation relies on a combination of histological assessment, immunohistochemistry and molecular testing to determine morphology, viral status and genetic alterations. Contemporary classification schemes, notably the International Endocervical Adenocarcinoma Criteria and Classification (IECC), distinguish usual-type, gastric-type and other variant adenocarcinomas on the basis of cytomorphology, mucin profiles and HPV biomarkers. Diagnostic work-up begins with cytological screening and high-risk HPV testing, progressing to colposcopic-guided biopsy for histopathological evaluation. Immunohistochemical panels incorporating p16, p53 and lineage-specific mucins (for example MUC6) refine subtype assignment and inform prognosis. Molecular techniques such as in situ hybridisation for HPV, fluorescence in situ hybridisation for gene amplifications (for example HER2) and next-generation sequencing for key driver mutations further enhance precision diagnostics. Recent advances in digital pathology and artificial intelligence have begun to standardise pattern-based classifications and reduce interobserver variability. Accurate subtyping underpins tailored management strategies, ranging from fertility-sparing surgery in low-risk cases to chemoradiation or targeted therapy in aggressive variants, and is vital for global screening and vaccination impact assessments.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Endocervical Adenocarcinoma Characterization and Diagnostic Techniques publication trend

The graph below shows the total number of articles in endocervical adenocarcinoma characterization and diagnostic techniques across all publications each year (not limited to Nature Index journals).

Technical terms

Endocervical adenocarcinoma: A malignant glandular tumour arising from the mucin-producing epithelium of the endocervical canal.

Human papillomavirus-associated: Tumours linked to high-risk HPV types, typically demonstrating diffuse p16 positivity.

Human papillomavirus-independent: Adenocarcinomas not driven by HPV infection, often corresponding to gastric-type or other rare variants.

International Endocervical Adenocarcinoma Criteria and Classification (IECC): A morphology-based system that categorises endocervical adenocarcinomas by HPV association and histological subtype.

Silva pattern-based classification (SPBC): A scheme for HPV-associated invasive adenocarcinoma that stratifies tumours by destructive stromal invasion patterns.

Immunohistochemistry (IHC): A laboratory technique using antibodies to detect specific protein markers in tissue sections.

Fluorescence in situ hybridisation (FISH): A molecular cytogenetic method for identifying gene amplifications or translocations within tumour cells.

Deep learning system (DLS): An artificial intelligence approach employing neural networks to analyse histopathological images and assist classification.

References

1. Development and validation of a deep learning algorithm for pattern-based classification system of cervical cancer from pathological sections. Heliyon (2023).
2. Tumor Typing of Endocervical Adenocarcinoma: Contemporary Review and Recommendations From the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology (2021).
3. An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification. The Journal of Pathology Clinical Research (2020).
4. The Silva Pattern-based Classification for HPV-associated Invasive Endocervical Adenocarcinoma and the Distinction Between In Situ and Invasive Adenocarcinoma: Relevant Issues and Recommendations From the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology (2021).
5. HPV-Negative Adenocarcinomas of the Uterine Cervix: From Molecular Characterization to Clinical Implications. International Journal of Molecular Sciences (2022).